Figure 3From: Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD (A) OS by regimens (staged approach, PAD,VTD); (B) EFS by regimens (staged approach , PAD, VTD). Back to article page